米托蒽醌联合阿糖胞苷方案治疗急性非淋巴细胞白血病效果观察

摘要

Objective Discussion on clinical effect of mitoxantrone and cytarabine in the treatment of acute non-lymphocytic leukemia.Methods Depending on the treatment,from January 2014 to January 2015 102 cases of acute non-lymphocytic leukemia in our hospital were divided into control group and study group and the control group were treated with daunorubicin and cytarabine therapy,study group treated with mitoxantrone and cytarabine therapy,and clinical outcomes of patients were compared.ResultsThe total effective rate of the study group was better than that of the control group, the difference was statisticaly significant(P<0.05). The difference between the two groups in addition to bone marrow suppression was significantly significant(P<0.05),the gastrointestinal tract,liver and renal function difference was not statisticaly significant(P>0.05).Conclusion Mitoxantrone combined with cytarabine in the treatment of acute non-lymphocytic leukemias have good clinical results,be used as an ideal therapeutic drug for acute non lymphatic leukemia.%目的：探讨米托蒽醌联合阿糖胞苷方案治疗急性非淋巴细胞白血病的临床效果。方法根据治疗药物的不同将2014年1月～2015年1月在我院住院的102例急性非淋巴细胞白血病患者分为对照组和研究组，对照组患者采用柔红霉素联合阿糖胞苷治疗，研究组患者采用米托蒽醌联合阿糖胞苷治疗，并比较两组患者临床治疗效果。结果研究组患者临床治疗总有效率优于对照组患者，两组比较差异具有统计学意义（P＜0.05）；两组患者除骨髓抑制差异具有统计学意义（P＜0.05）外，胃肠道反应、肝肾功能等比较差异无统计学意义（P＞0.05）。结论米托蒽醌结合阿糖胞苷在治疗急性非淋巴性白血病方面临床效果较好，可作为急性非淋巴性白血病的理想治疗药物进行选择。